Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).
James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.
Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
